TSE:APS

Aptose Biosciences Q4 2025 Earnings Results & Report

Aptose Biosciences logo
C$2.40 0.00 (0.00%)
As of 07/3/2026

Aptose Biosciences reported Q4 2025 earnings on March 31, 2026. The company reported EPS of -C$4.07.

Earnings Announcement Details

Quarter
Q4 2025
Report Date
Time
After Market Closes

Aptose Biosciences EPS Results

Actual EPS
-C$4.07
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Aptose Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Aptose Biosciences Q4 2025 Earnings FAQ

Aptose Biosciences (TSE:APS) reported earnings of -C$4.07 per share for Q4 2025. The report was announced on Tuesday, March 31, 2026.

Aptose Biosciences Earnings Headlines

The $40 trillion number nobody won on Tuesday will touch
Democrats took the House and Senate on election night, but the $40 trillion national debt and the $1 trillion a year in interest on it didn't change. Central banks bought 863 tonnes of gold in 2025 and another 289 tonnes in the second quarter of this year. Gold broke $5,000 and had its best year since 1979 in 2025. Wall Street's biggest bank forecasts gold above $6,000 by early 2027.tc pixel
See More Aptose Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aptose Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aptose Biosciences and other key companies, straight to your email.

About Aptose Biosciences

Aptose Biosciences (TSE:APS), a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

View Aptose Biosciences Profile